Life-Saving Drug or Potential Threat? The Role of Mineralocorticoid Receptor Antagonists in Myocardial Infarction: A Meta-Analysis
Pooled result · Death from any causeResult — go to the resultRelative risk 0.87 95% CI 0.79–0.95Authors' conclusion
MRAs improve cardiovascular outcomes in MI patients, especially in those with heart failure.
Study context
- Population
- Post-MI patients; RCTs from Web of Science, PubMed, Embase and Cochrane Library
- Participants
- 17,851 patients13 RCTs
- Comparison
- Mineralocorticoid receptor antagonists (MRAs) vs control
- Outcome
- Death from any cause
Methodological detailssubgroup analyses by heart failure and MRA type
- Subgroup analyses by heart failure and MRA type
Pooled result
As reported in the abstract
Relative risk
0.87
95% CI 0.79–0.95
P = 0.004
MRAsvs Control
RR 0.87 (95% CI 0.79–0.95); P = 0.004
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| Death from CV causes, HF subgroup | 0.87 (0.78–0.97) | |
| Death from CV causes, no-HF subgroupNo significant effect | 0.69 (0.34–1.38) | |
| 0.20.5125Relative risk (log scale) |
Subgroups by MRA drug
- Subgroup analysis by different MRA drugs showed varying effects on outcomes
Safety
Hyperkalemia
- Hyperkalemia significantly more frequent (RR 1.95; 95% CI 1.55-2.46; P < .01)
Other safety events (hypokalemia, breast tenderness, gynecomastia)
- Other safety events did not show significant differences
Original publication
Life-Saving Drug or Potential Threat? The Role of Mineralocorticoid Receptor Antagonists in Myocardial Infarction: A Meta-Analysis. Endocr Pract. Published 8 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →